B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025
상품코드:1716921
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
B세포 성숙 항원(BCMA) 표적치료 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 CAGR 24.6%로 366억 6,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장의 원동력은 암 연구에 대한 지속적인 집중, 특정 분자 마커를 표적으로 삼는 방향으로의 전환, 암 발병률 증가, 생명공학에 대한 투자 급증, 세포 및 유전자 치료의 사용 확대 등입니다. 예측 기간의 주요 동향으로는 CRISPR 기술 등의 발전, 유전자 편집 기술의 발전, 차세대 CAR-T 세포치료제 개발, 표적 항체약물접합체의 발전, 기성품 치료제의 창출 등을 들 수 있습니다.
다발성골수종 유병률 증가는 B세포 성숙 항원(BCMA) 표적치료제 시장의 성장을 촉진할 것으로 예측됩니다. 다발성골수종은 주로 형질세포(항체 생산을 담당하는 면역체계의 중요한 컴포넌트)에 영향을 미치는 암으로, 전 세계에서 고령화, 진단 툴의 향상, 의료 서비스 접근성 향상 등의 요인으로 인해 더욱 보편화되고 있으며, BCMA 표적 치료는 BCMA를 발현하는 악성 형질세포의 제거에 초점을 맞추었습니다. 세포의 제거에 초점을 맞추고, 보다 정확하고 효과적인 치료법을 제공하므로 이 질환의 치료에 필수적입니다. 예를 들어 미국암협회는 2024년 미국에서 약 35,780명(남성 19,520명, 여성 16,260명)의 다발성골수종 환자가 새로 발생할 것으로 예측했습니다. 예상 사망자 수는 약 1만 2,540명(남성 7,020명, 여성 5,520명)입니다. 결과적으로 이러한 암 발병률 증가는 BCMA 표적치료제 시장의 성장에 박차를 가하고 있습니다.
B세포 성숙항원(BCMA) 표적치료제 시장의 주요 업체들은 암세포 표적치료의 효과와 정확성을 높이기 위해 CAR-T 세포치료제와 같은 첨단 치료법 개발에 주력하고 있습니다. 암세포를 특이적으로 공격하고 제거할 수 있도록 하는 면역치료제입니다. 예를 들어 2024년 4월 미국 제약사 존슨앤드존슨이 미국 식품의약국(FDA)으로부터 CARVYKTI(ciltacabtagene autoleucel)를 승인받았는데, 이는 BCMA를 표적으로 하는 유전자 재조합 자가 T세포 치료제입니다. 레날리도마이드에 내성을 보이는 재발성 또는 불응성 다발성골수종 성인 환자를 치료하기 위해 개발되었습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 B세포 성숙 항원(BCMA) 표적치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 성장률 분석
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 실적 : 규모와 성장, 2019-2024
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 B세포 성숙 항원(BCMA) 표적치료 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항체약물접합체
키메라 항원 수용체 T(CAR-T) 세포치료
이중특이성항체
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
급성 림프성 백혈병
다발성골수종
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
홈케어 설정
세계의 B세포 성숙 항원(BCMA) 표적치료 시장, 항체약물접합체의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
BCMA 표적 ADC(항체약물접합체)
링커 페이로드 기술 기반 BCMA ADC
세계의 B세포 성숙 항원(BCMA) 표적치료 시장, 키메라 항원 수용체 T(CAR-T) 세포치료의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
BCMA CAR-T세포(자기)
동종 BCMA CAR-T세포
세계의 B세포 성숙 항원(BCMA) 표적치료 시장, 이중특이성항체의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
BCMA x CD3 이중특이성항체
BCMA x CD28 이중특이성항체
제7장 지역별·국가별 분석
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 B세포 성숙 항원(BCMA) 표적치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
B세포 성숙 항원(BCMA) 표적치료 시장 : 경쟁 구도
B세포 성숙 항원(BCMA) 표적치료 시장 : 기업 개요
Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Novartis Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline(GSK) Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Regeneron Pharmaceuticals
Beigene
Arcellx Inc
Poseida Therapeutics
Legend Biotech Corporation
Cartesian Therapeutics
Juno Therapeutics
Sutro Biopharma Inc
CARsgen Therapeutics
Precision BioSciences
Eureka Therapeutics Inc
Cellectis
Teneobio Inc.
Janssen Pharmaceuticals Companies
Allogene Therapeutics
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
B세포 성숙 항원(BCMA) 표적치료 시장 2029 : 새로운 기회를 제공하는 국가
B세포 성숙 항원(BCMA) 표적치료 시장 2029 : 새로운 기회를 제공하는 부문
B세포 성숙 항원(BCMA) 표적치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
B-cell maturation antigen (BCMA) targeted therapies are a class of treatments designed to specifically target BCMA, a protein found on the surface of mature B-cells and plasma cells. BCMA, a member of the tumor necrosis factor (TNF) receptor superfamily, plays an essential role in B-cell development, survival, and differentiation into plasma cells. These therapies represent a significant advancement in treating multiple myeloma, providing effective options for patients with relapsed or refractory disease.
The main types of products in BCMA-targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. ADCs are targeted treatments that attach a cancer-specific antibody to a cytotoxic drug, allowing for the precise destruction of cancer cells while minimizing damage to healthy tissue. The primary indications for these therapies include acute lymphoblastic leukemia and multiple myeloma. These treatments are used by various end users, such as hospitals, specialty clinics, and home care settings.
The B-cell maturation antigen (BCMA) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides B-cell maturation antigen (BCMA) targeted therapies market statistics, including the B-cell maturation antigen (BCMA) targeted therapies industry global market size, regional shares, competitors with the B-cell maturation antigen (BCMA) targeted therapies market share, detailed B-cell maturation antigen (BCMA) targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the B-cell maturation antigen (BCMA) targeted therapies industry. This B-cell maturation antigen (BCMA) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.21 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth during the historical period can be attributed to an increasing focus on hematologic malignancies, rising investments in oncology research, a growing demand for personalized medicine, higher adoption of CAR-T cell therapies, and rising healthcare expenditure.
The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $36.66 billion in 2029 at a compound annual growth rate (CAGR) of 24.6%. The expected growth in the forecast period is driven by a continued focus on cancer research, a shift toward targeting specific molecular markers, the rising incidence of cancers, a surge in biotech investments, and the expanding use of cell and gene therapies. Key trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, the development of next-generation CAR-T cell therapies, progress in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.
The growing prevalence of multiple myeloma is anticipated to drive the expansion of the B-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer that mainly impacts plasma cells-vital components of the immune system responsible for antibody production-is becoming more common due to factors such as an aging global population, enhanced diagnostic tools, and varying levels of healthcare access. BCMA-targeted therapies are essential for treating this condition, as they focus on eliminating malignant plasma cells expressing BCMA, offering a more precise and effective treatment option. For example, the American Cancer Society projected that in 2024, the United States would see approximately 35,780 new multiple myeloma cases, including 19,520 in men and 16,260 in women. The expected death toll is around 12,540, with 7,020 male deaths and 5,520 female deaths. As a result, the increasing incidence of this cancer is fueling growth in the BCMA-targeted therapies market.
Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing cutting-edge treatments such as CAR-T cell therapy to improve the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy is an immunotherapy that involves altering a patient's T cells to express chimeric antigen receptors (CARs), enabling them to specifically attack and eliminate cancer cells. For example, in April 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma who have undergone at least one previous line of treatment and are resistant to lenalidomide.
In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for around $1.2 billion. This acquisition is aimed at strengthening AstraZeneca's cell therapy portfolio by incorporating Gracell's FasTCAR-enabled GC012F therapy, which targets cancer and autoimmune diseases, addressing critical unmet medical needs. Gracell Biotechnologies, based in China, specializes in developing BCMA therapies for multiple myeloma and B-cell malignancies.
Major players in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in B-cell maturation antigen (BCMA) targeted therapies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on b-cell maturation antigen (bcma) targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for b-cell maturation antigen (bcma) targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The b-cell maturation antigen (bcma) targeted therapies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
3) By End User: Hospitals; Specialty Clinics; Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies
4. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Analysis And Strategic Analysis Framework
5.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibody Drug Conjugates
Chimeric Antigen Receptor T (CAR-T)-Cell Therapy
Bispecific Antibodies
6.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Lymphoblastic Leukemia
Multiple Myeloma
6.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Home Care Settings
6.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA-Targeted ADCs (Antibody-Drug Conjugates)
Linker-Payload Technology-Based BCMA ADCs
6.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA CAR-T Cells (Autologous)
Allogeneic BCMA CAR-T Cells
6.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA x CD3 Bispecific Antibodies
BCMA x CD28 Bispecific Antibodies
7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional And Country Analysis
7.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
9.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
9.2. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
10.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
11.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
11.2. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
12.1. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
13.1. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
14.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
14.2. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
15.1. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
15.2. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
16.1. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.2. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
22.1. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
23.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
23.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
24.1. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
24.2. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
26.1. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
26.2. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
27.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
